NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Active Not RecruitingPhase 2

Sponsor: The Netherlands Cancer Institute

Conditions: Stomach Cancer, Gastro Esophageal Junction Cancer

Interventions: Atezolizumab, Capecitabine, Oxaliplatin, Docetaxel

Countries: Netherlands

In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment. The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* signed informed consent
* patients age 18 and older
* primary resectable, histologically confirmed gastric or GEJ adenocarcinoma

Exclusion Criteria:

* no signs of distant metastases
* no active or history of autoimmune disease or immune deficiency
* no significant cardiovascular disease
* no major surgical procedure within 4 weeks prior to initiation of study treatment
* no current treatment with anti-viral therapy or HBV
* no pregnancy or breastfeeding
* no history of malignancy within 3 years prior to screening

Locations (2)

Amsterdam, Netherlands
Eindhoven, Netherlands